stockrow
Saturday 7 November 2026
Export EIKN’s income statement to Excel — free account
Eikon Therapeutics, Inc.
EIKN Healthcare Biotechnology
5.92
0.08
+1.37%
Follow EIKN
Alert me
Eikon Therapeutics, Inc. (EIKN) P/E ratio
Eikon Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRD Opus Genetics, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| PROK ProKidney Corp. compare | n/m |
| EIKN Eikon Therapeutics, Inc. | n/m |
| FENC Adherex Technologies Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. compare | 6.6× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)